Literature DB >> 24253371

Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

Laurence Rozen1, Sophie Huybrechts, Laurence Dedeken, Catherine Heijmans, Barbara Dessars, Pierre Heimann, Frédéric Lambert, Denis F Noubouossie, Alina Ferster, Anne Demulder.   

Abstract

UNLABELLED: Transient neonatal leukemia occurs almost exclusively in Down syndrome babies. We report here the unusual case of a newborn without Down syndrome who presented neonatal transient leukemia and who achieved spontaneously complete remission. Trisomy 21 and GATA1 mutation were both present in leukemic cells. While close follow-up is advised since true leukemia may develop later, the patient is still in remission for 2.5 years. We performed a literature review of 15 other similar cases.
CONCLUSION: Our case of transient leukemia without Down syndrome and the literature review highlight the important role of trisomy 21 and GATA1 mutation in the development of transient neonatal leukemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24253371     DOI: 10.1007/s00431-013-2163-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  34 in total

Review 1.  Down syndrome and the transient myeloproliferative disorder: why is it transient?

Authors:  Jeffrey W Taub; Yaddanapudi Ravindranath
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

2.  Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.

Authors:  Hiroto Inaba; Margherita Londero; Scott H Maurer; Mihaela Onciu; Yubin Ge; Jeffrey W Taub; Jeffrey E Rubnitz; Susana C Raimondi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

3.  GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

Authors:  Emily Carpenter; Veronica Valverde-Garduno; Alex Sternberg; Chris Mitchell; Irene Roberts; Paresh Vyas; Ajay Vora
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

Review 4.  Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.

Authors:  Anindita Roy; Irene Roberts; Paresh Vyas
Journal:  Semin Fetal Neonatal Med       Date:  2012-03-14       Impact factor: 3.926

Review 5.  Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate.

Authors:  Jacek M Polski; Csaba Galambos; Gordon B Gale; Cherie H Dunphy; H Lance Evans; Jacqueline R Batanian
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

6.  Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.

Authors:  Thomas Cushing; Carol L Clericuzio; Carla S Wilson; Jeffrey W Taub; Yubin Ge; Kaaren K Reichard; Stuart S Winter
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

7.  Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.

Authors:  Isis Quezado Magalhães; Alessandra Splendore; Mariana Emerenciano; Mara Santos Córdoba; Jose Carlos Córdoba; Paula Azevedo Allemand; Iris Ferrari; Maria S Pombo-de-Oliveira
Journal:  J Pediatr Hematol Oncol       Date:  2005-01       Impact factor: 1.289

8.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Authors:  Johann K Hitzler; Joseph Cheung; Yue Li; Stephen W Scherer; Alvin Zipursky
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

Review 9.  Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.

Authors:  Sandeep Gurbuxani; Paresh Vyas; John D Crispino
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

10.  Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome.

Authors:  M D Brissette; B J Duval-Arnould; B G Gordon; J D Cotelingam
Journal:  Am J Hematol       Date:  1994-12       Impact factor: 10.047

View more
  5 in total

Review 1.  Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Authors:  Rintaro Ono; Daisuke Hasegawa; Shinsuke Hirabayashi; Takahiro Kamiya; Kenichi Yoshida; Satoko Yonekawa; Chitose Ogawa; Ryota Hosoya; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Atsushi Manabe
Journal:  Eur J Pediatr       Date:  2014-09-30       Impact factor: 3.183

2.  Donor cell-derived transient abnormal myelopoiesis as a specific complication of umbilical cord blood transplantation.

Authors:  N Hiramoto; J Takeda; K Yoshida; Y Ono; S Yoshioka; N Yamauchi; A Fujimoto; H Maruoka; Y Shiraishi; H Tanaka; K Chiba; Y Imai; S Miyano; S Ogawa; T Ishikawa
Journal:  Bone Marrow Transplant       Date:  2017-10-09       Impact factor: 5.483

3.  Transient myeloproliferative disorder as the presenting feature for mosaic trisomy 21.

Authors:  Nicole Baca; Pedro A Sanchez-Lara; Rhona Schreck; Celeste C Eno; Fataneh Majlessipour
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

4.  Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn.

Authors:  Rahela Aziz-Bose; Franziska Wachter; Roberto Chiarle; Neal I Lindeman; Annette S Kim; Barbara A Degar; Kimberly Davies; Yana Pikman
Journal:  Blood Adv       Date:  2022-05-10

5.  Transient Abnormal Myelopoiesis: A Varied Spectrum of Clinical Presentation.

Authors:  Amitabh Singh; Anirban Mandal; Vijay Guru; Sindhu Srinivasan; Rachna Seth
Journal:  J Hematol (Brossard)       Date:  2017-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.